-
Story
Drug delivery, service delivery, and the future of cancer care -
Press Release
Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
-
Story
Prostate Cancer: A collective commitment to serving underserved communities -
Press Release
Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021
-
Press Release
Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients
-
Press Release
New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis
-
Press Release
Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria
-
Press Release
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
-
Press Release
Novartis completes tender offer for all outstanding shares of The Medicines Company
-
Press Release
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
-
Story
Your Genes, Your Melanoma -
Story
Meet T.J. Sharpe